Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Subscribe To Our Newsletter & Stay Updated
